S&P 500   3,264.28 (+0.85%)
DOW   26,962.86 (+0.75%)
QQQ   266.57 (+0.91%)
AAPL   109.25 (+1.99%)
MSFT   204.41 (+1.90%)
FB   249.82 (+0.32%)
GOOGL   1,423.73 (+1.02%)
AMZN   3,042.16 (+1.41%)
NVDA   498.40 (+2.77%)
TSLA   393.01 (+3.33%)
BABA   269.48 (-1.27%)
CGC   14.43 (-1.16%)
GE   6.08 (-0.49%)
MU   49.70 (-0.30%)
AMD   76.30 (+2.10%)
T   28.01 (+0.50%)
F   6.62 (-0.30%)
ACB   5.21 (+0.77%)
GILD   62.31 (-1.24%)
NFLX   472.55 (+0.41%)
DIS   122.52 (-0.62%)
BAC   23.50 (+1.03%)
BA   146.31 (-3.22%)
S&P 500   3,264.28 (+0.85%)
DOW   26,962.86 (+0.75%)
QQQ   266.57 (+0.91%)
AAPL   109.25 (+1.99%)
MSFT   204.41 (+1.90%)
FB   249.82 (+0.32%)
GOOGL   1,423.73 (+1.02%)
AMZN   3,042.16 (+1.41%)
NVDA   498.40 (+2.77%)
TSLA   393.01 (+3.33%)
BABA   269.48 (-1.27%)
CGC   14.43 (-1.16%)
GE   6.08 (-0.49%)
MU   49.70 (-0.30%)
AMD   76.30 (+2.10%)
T   28.01 (+0.50%)
F   6.62 (-0.30%)
ACB   5.21 (+0.77%)
GILD   62.31 (-1.24%)
NFLX   472.55 (+0.41%)
DIS   122.52 (-0.62%)
BAC   23.50 (+1.03%)
BA   146.31 (-3.22%)
S&P 500   3,264.28 (+0.85%)
DOW   26,962.86 (+0.75%)
QQQ   266.57 (+0.91%)
AAPL   109.25 (+1.99%)
MSFT   204.41 (+1.90%)
FB   249.82 (+0.32%)
GOOGL   1,423.73 (+1.02%)
AMZN   3,042.16 (+1.41%)
NVDA   498.40 (+2.77%)
TSLA   393.01 (+3.33%)
BABA   269.48 (-1.27%)
CGC   14.43 (-1.16%)
GE   6.08 (-0.49%)
MU   49.70 (-0.30%)
AMD   76.30 (+2.10%)
T   28.01 (+0.50%)
F   6.62 (-0.30%)
ACB   5.21 (+0.77%)
GILD   62.31 (-1.24%)
NFLX   472.55 (+0.41%)
DIS   122.52 (-0.62%)
BAC   23.50 (+1.03%)
BA   146.31 (-3.22%)
S&P 500   3,264.28 (+0.85%)
DOW   26,962.86 (+0.75%)
QQQ   266.57 (+0.91%)
AAPL   109.25 (+1.99%)
MSFT   204.41 (+1.90%)
FB   249.82 (+0.32%)
GOOGL   1,423.73 (+1.02%)
AMZN   3,042.16 (+1.41%)
NVDA   498.40 (+2.77%)
TSLA   393.01 (+3.33%)
BABA   269.48 (-1.27%)
CGC   14.43 (-1.16%)
GE   6.08 (-0.49%)
MU   49.70 (-0.30%)
AMD   76.30 (+2.10%)
T   28.01 (+0.50%)
F   6.62 (-0.30%)
ACB   5.21 (+0.77%)
GILD   62.31 (-1.24%)
NFLX   472.55 (+0.41%)
DIS   122.52 (-0.62%)
BAC   23.50 (+1.03%)
BA   146.31 (-3.22%)
Log in
CVE:ATE

Antibe Therapeutics Price Target, Predictions & Analyst Ratings

C$0.34
-0.01 (-2.90 %)
(As of 09/24/2020 11:50 AM ET)
Add
Compare
Today's Range
C$0.33
Now: C$0.34
C$0.34
50-Day Range
C$0.35
MA: C$0.39
C$0.45
52-Week Range
C$0.33
Now: C$0.34
C$0.89
Volume439,905 shs
Average Volume1.50 million shs
Market CapitalizationC$129.13 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Analyst Ratings

Antibe Therapeutics (CVE:ATE) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Antibe Therapeutics in the last 12 months. Their average twelve-month price target is C$1.50, predicting that the stock has a possible upside of 347.76%. The high price target for ATE is C$1.50 and the low price target for ATE is C$1.50. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
ATE Consensus Rating: BuyBuyN/AN/A
ATE Consensus Rating Score: 2.502.50N/AN/A
ATE Analyst Ratings: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
ATE Consensus Price Target: C$1.50C$1.50N/AN/A
ATE Price Target Upside: 347.76% upsideN/AN/AN/A

Antibe Therapeutics (CVE:ATE) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Antibe Therapeutics (CVE:ATE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/17/2020Canaccord GenuitySet Price TargetSpeculative BuyC$1.50
7/15/2020Brookline Capital ManagementReiterated RatingBuy
(Data available from 9/24/2018 forward)
This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.